CJC 1295 (no dac)10mg vial

CJC-1295 No DAC

What is CJC-1295 No DAC?

CJC-1295 No DAC, also known as Modified GRF (1-29) or Mod GRF (1-29), is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone (GHRH). It has the molecular formula C₁₅₂H₂₅₂N₄₄O₄₂, a molecular weight of approximately 3367.9 g/mol, and the CAS number 863288-34-0.

Unlike CJC-1295 DAC, this variant does not contain the Drug Affinity Complex (DAC) modification, resulting in a shorter duration of biological activity. It is widely used as a research peptide for investigating growth hormone-releasing hormone receptor signalling and endocrine physiology.

Hybrid 2.0 supplies CJC-1295 No DAC exclusively as a lyophilised peptide for laboratory and scientific research.

Chemical Identifiers

CAS Number: 863288-34-0

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

Molecular Weight: 3367.9 g/mol

PubChem CID: 56841945

Legal Status in the UK

CJC-1295 No DAC is not a controlled drug under the Misuse of Drugs Act 1971 and is not a scheduled substance.

It is not authorised by the MHRA as a licensed medicine and must not be supplied, marketed or used for human or veterinary consumption.

Hybrid 2.0 supplies this peptide strictly for laboratory and scientific research. Purchasers are responsible for complying with all applicable laws and regulations.

Mechanism of Action

CJC-1295 No DAC functions as an analogue of growth hormone-releasing hormone (GHRH), binding to GHRH receptors located on somatotroph cells within the anterior pituitary gland.

Experimental research has shown that activation of these receptors stimulates physiological growth hormone signalling pathways. Because this analogue lacks the Drug Affinity Complex (DAC) modification, it exhibits a shorter biological activity than the DAC-modified form, making it useful for comparative studies of GHRH receptor pharmacology and endocrine regulation.

Areas of Research Interest

Current scientific research is investigating CJC-1295 No DAC in relation to:

Growth hormone-releasing hormone receptor signalling

Growth hormone physiology

Endocrine regulation

IGF-1 signalling pathways

Neuroendocrine physiology

Peptide pharmacology

Comparative GHRH analogue research

These remain active areas of scientific investigation and should not be interpreted as established therapeutic uses.

Current Research Applications

CJC-1295 No DAC is commonly investigated in research relating to:

Endocrinology

Growth hormone physiology

Receptor pharmacology

Peptide signalling

Neuroendocrine research

Experimental metabolic physiology

Comparative peptide research

These applications are intended solely for laboratory and scientific investigation and should not be interpreted as evidence of clinical efficacy.

Summary

CJC-1295 No DAC is a short-acting GHRH analogue that remains an important research tool for investigating endogenous growth hormone signalling and endocrine physiology. Ongoing studies continue to explore its receptor interactions, pharmacological characteristics and role within experimental models of hormone regulation.

Research Disclaimer

For Research Use Only. Not for human consumption or veterinary use. Products supplied by Hybrid 2.0 are intended strictly for laboratory and scientific research purposes. Any information provided is for educational and scientific discussion only and should not be interpreted as medical advice, therapeutic claims, or evidence of clinical efficacy.